RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Marcatori molecolari nel carcinoma del cavo orale e loro impiego nella diagnosi precoce, nella prognosi e nella risposta ai farmaci antiblastici.
• 2 - Sviluppo e progressione del carcinoma epatocellulare: meccanismi molecolari ed implicazioni terapeutiche
• 3 - Studio delle alterazioni biomolecolari e dei profili di espressione genica nel carcinoma colorettale e pancreatico: identificazione di possibili elementi prognostici e bersagli terapeutici nel sistema degli eicosanoidi e dei cannabinoidi.
• 4 - Carcinoma papillare della tiroide sdifferenziato: caratteristiche cliniche, cellulari, molecolari; sintesi e farmacologia preclinica di nuovi agenti terapeutici inibitori delle tirosinchinasi.
• 5 - Meccanismi di controllo dell’eritropoiesi e policitemie congenite e familiari: ruolo delle vie di risposta alla pressione di ossigeno
• 6 - Fisiopatologia,clinica e terapia dei tumori corticosurrenalici
• 7 - Meccanismi molecolari di carcinogenesi: validazione di nuovi bersagli per la diagnosi e la terapia
• 8 - Un modello di progressione neoplastica per il carcinoma del cavo orale: studio genomico e proteomico in vivo ed in vivo di linee cellulari e subcloni ad elevata aggressività. Correlazioni con la progressione neoplastica.
• 9 - Variabilità e funzione delle mutazioni mitocondriali in condizioni fisiologiche e patologiche
• 10 - Studio sui rapporti tra autoimmunità tiroidea e tumori della tiroide

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • ANATOMIA PATOLOGICA
  • CHIRURGIA GENERALE
  • DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Piemonte

Bibliografia

1-Stomper PC, Connolly JL, Meyer JE, et al. Clinically occult ductal carcinoma in situ detected with mammography: analysis of 100 cases with radiologic-pathologic correlation. Radiology, 1989;172:234-41
2-Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ. N Engl J 2004;350:1430-41
3-Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathos 1994;11:167-80
4-Foschini MP, Fornelli A, Peterse JL, et al. Microcalcifications in ductal carcinoma in situ of the breast. Hum Pathol. 1996;27:178-83
5-Bobrow LG, Happerfield LC, Gregory WM, et al. The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 1994;11:199-207
6-Eusebi V, Feudale E, Foschini MP, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994;11:223-35
7-Sapino A, Frigerio A, Peterse JL, et al. Mammographically detected in situ lobular carcinomas of the breast. Virchows Arch 2000;436:421-30
8-Volante M, Sapino A, Croce S, et al. Heterogeneous versus homogeneous genetic nature of multiple foci of in situ carcinoma of the breast. Hum Pathol 2003;34:1163-9
9-Bijker N, Peterse JL, Duchateau L, et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2001;84:539-44
10-Lampejo OT, Barnes DM, Smith P, et al. Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component. Semin Diagn Pathol 1994;11:215-22.
11-Millis RR, Barnes DM, Lampejo OT, et al. Tumour grade does not change between primary and recurrent mammary carcinoma. Eur J Cancer 1998;34:548-53
12-WHO Tumours of the breast and female genitalorgans. Tavassoli FA, Devilee P 3rd(5th). 2003. IARC Press Lyon. WHO classification of tumours. Kleihues P, Sobin L
13-Tabar L, Tony Chen HH, Amy Yen MF, et al. Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma. Cancer 2004;101:1745-59
14-Zaugg K, Bodis S. Is there a role for molecular prognostic factors in the clinical management of ductal carcinoma in situ (DCIS) of the breast? Radiother Oncol 2000;55:95-9
15-Senn HJ, Thurlimann B, Goldhirsch A, et al. Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. Breast 2003;12:569-82
16-Chasle J, Delozier T, Denoux Y, et al. Immunohistochemical study of cell cycle regulatory proteins in intraductal breast carcinomas:a preliminary study. Eur J Cancer 2003;39:1363-9
17-Sapino A, Bongiovanni M, Cassoni P, et al. Expression of CD31 by cells of extensive ductal in situ and invasive carcinomas of the breast. J Pathol 2001;194:254-61
18-Righi L, Deaglio S, Pecchioni C, et al. Role of CD31/platelet endothelial cell adhesion molecule-1 expression in in vitro and in vivo growth and differentiation of human breast cancer cells. Am J Pathol 2003;162:1163-74
19-Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12
20-Sapino A, Coccorullo Z, Cassoni P, et al. Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains. Histopathology 2003;43:354-62
21-Bussolati G, Montemurro F, Righi L, et al. A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. Br J Cancer 2005;92:1261-7
22-Osborne CK, Shou J, Massarweh S, et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11:865s-70s
23-Allred DC, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24. Breast Cancer Res Treat 2002;76:S36
24-Collins LC, Schnitt SJ. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol. 2005;Jan 14
25-Chan KC, Knox WF, Gandhi A, et al. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg. 2001;88:412-18
26-Quaglino E, Iezzi M, Mastini C, et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res. 2004;64:2858-64
27-Silverstein MJ. An argument against routine use of radiotherapy for ductal carcinoma in situ. Oncology (Huntingt). 2003;17:1511-33;discussion 1533-4,1539,1542
28-Houghton J, George WD, Cuzick J, et al.;UK Coord. Comm. on Cancer Research;DCIS Working Party;DCIS trialists in the UK, Australia & New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia & New Zealand: randomised controlled trial. Lancet 2003;362:95-102
29-Bussolati G, Bongiovanni M, Cassoni P, et al. Assessment of necrosis and hypoxia in ductal carcinoma in situ of the breast: basis for a new classification. Virchows Arch 2000;437:360-4
30-Okunieff P, Hoeckel M, Dunphy EP, et al. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys 1993;26:631-6
31-Hill RP, Stanley JA. The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents. Cancer Res 1975;35:1147-53
32-Teicher BA. Related Hypoxia and drug resistance. Cancer Metastasis Rev 1994;13:139-68
33-Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981;41:73-81
34-Harris AL. Hypoxia:a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47
35-Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-32
36-Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001;107:1-3
37-Ivan M, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev 2001;11:27-34
38-Ratcliffe PJ, O'Rourke JF, Maxwell PH, et al. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998;201:1153-62
39-Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 200;60:1541-5
40-Feldser D, Agani F, Iyer NV, et al. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 1999;59:3915-8
41-Jiang BH, Semenza GL, Bauer C, et al. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996;271:C1172-80
42-Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001;93:309-14
43-Bos R, van Diest PJ, van der Groep P, et al. Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related. Breast Cancer Res 2004;6:R450-9
44-Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000;14:391-6
45-Birner P, Schindl M, Obermair A, et al. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7:1661-8
46-Morandi L, Pession A, Marucci GL, et al. Intraepidermal cells of Paget's carcinoma of the breast can be genetically different from those of the underlying carcinoma. Hum Pathol 2003;34:1321-30

Parole Chiave

CARCINOMA DUTTALE IN SITU; DIAGNOSI; IMMUNOCITOCHIMICA; BIOLOGIA MOLECOLARE; TIPIZZAZIONE BIOLOGICA; FOLLOW-UP; TERAPIA